NY-ESO-1-Specific (c259) T Cells are a type of genetically engineered immune cell therapy. These T cells are designed to recognize and attack cancer cells that express specific proteins called NY-ESO-1 and LAGE-1a. The therapy involves collecting T cells from the patient, modifying them in a laboratory to target these proteins, and then infusing them back into the patient to help fight the cancer.

Anti-Cancer Agents are medications used in combination with the NY-ESO-1-specific (c259) T cells to enhance their effectiveness. These agents work in various ways to help stop the growth of cancer cells, kill them, or prevent them from spreading. The specific anti-cancer agents used in the trial are not named, but they are chosen to complement the action of the T cell therapy.

Synovial Sarcoma – This is a rare type of cancer that usually occurs near the joints of the arm, neck, or leg. It is characterized by the presence of spindle cells and can affect both soft tissues and bones. The disease often begins as a slow-growing mass, which may not cause symptoms until it becomes larger. As it progresses, it can invade nearby tissues and may spread to other parts of the body, such as the lungs. Synovial sarcoma is more common in young adults and adolescents.

Myxoid/Round Cell Liposarcoma (MRCLS) – This is a subtype of liposarcoma, a cancer that arises in fat cells in deep soft tissue. It is characterized by a mix of myxoid (mucous-like) and round cell components. The disease typically presents as a painless, enlarging mass in the thigh or retroperitoneum. As it progresses, it can infiltrate surrounding tissues and has the potential to metastasize, particularly to the lungs. MRCLS is more frequently diagnosed in adults and can vary in its rate of growth and spread.